Drugs Information:
Tocilizumab
Basic Information
|
||
| ID | DDInter1824 | |
| Drug Type | biotech | |
| Protein Chemical Formula | C6428H9976N1720O2018S42 | |
| Protein Average Weight | 148000.000 | |
| CAS Number | 375823-41-9 | |
| Description | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.[L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies.[A193281] Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome.[L12789] It was later approved by Health Canada on 30 April 2010.[L43697] After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation.[L40164] Subsequently, it was granted approval by Health Canada and the FDA in October [L43697] and December 2022, respectively.[L44483] | |
| ATC Classification | L04AC07 | |
| Sequences | >Tocilizumab light chain: DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPS RFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC | |
| Useful Links | DrugBank PubChem Substance KEGG Drug PharmGKB Wikipedia ChEMBL | |
Interactions with
Tocilizumab
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|